Seres Therapeutics (MCRB) : Traders are bullish on Seres Therapeutics (MCRB) as it has outperformed the S&P 500 by a wide margin of 16.4% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 19.84%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 20.48% in the last 1 week, and is up 14.04% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 14.07% and the 50-Day Moving Average is 29.16%.The 200 Day SMA reached 52.17% Seres Therapeutics, Inc. has dropped 57.16% during the last 3-month period . Year-to-Date the stock performance stands at -64.12%.
Seres Therapeutics (MCRB) : 4 Wall Street analysts covering Seres Therapeutics (MCRB) believe that the average level the stock could reach for the short term is $15.5. The maximum price target given is $23 and the minimum target for short term is around $12, hence the standard deviation is calculated at $5.2.
For the current week, the company shares have a recommendation consensus of Buy. Seres Therapeutics (NASDAQ:MCRB): The stock opened at $12.45 and touched an intraday high of $12.7 on Friday. During the day, the stock corrected to an intraday low of $11.76, however, the bulls stepped in and pushed the price higher to close in the green at $12.59 with a gain of 0.88% for the day. The total traded volume for the day was 941,184. The stock had closed at $12.59 in the previous trading session.
Seres Therapeutics, Inc. is a microbiome therapeutics platform company. The Company is engaged in developing a range of biological drugs, Ecobiotic microbiome therapeutics. It is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome in the human body. Its products include SER-109, which is designed to prevent further recurrences of Clostridium difficile infection, (CDI), a debilitating infection of the colon; SER-109; SER-262, and SER-155. Its SER-262 is a multi-strain Ecobiotic microbiome therapeutic to be used following antibiotic treatment of primary CDI to prevent an initial recurrence of CDI. The Company is developing SER-287 to treat ulcerative colitis. It is developing SER-155, which is an Ecobiotic microbiome therapeutic to treat enteric pathogens.